All Stories

  1. The genetics of amyotrophic lateral sclerosis: current insights
  2. Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis
  3. The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients
  4. Oligogenic inheritance of optineurin (OPTN) andC9ORF72mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions ofC9ORF72-ALS
  5. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions inAtaxin-2does not have 1C2-positive polyglutamine inclusions
  6. C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis
  7. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy
  8. Stratified gene expression analysis identifies major amyotrophic lateral sclerosis genes
  9. The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis
  10. Invited Review: Decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art
  11. Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions
  12. Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathology
  13. Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones
  14. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions
  15. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis
  16. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype
  17. Comparison of Blood RNA Extraction Methods Used for Gene Expression Profiling in Amyotrophic Lateral Sclerosis
  18. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions
  19. C9ORF72 transcription in a frontotemporal dementia case with two expanded alleles
  20. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis
  21. C9ORF72 expansions, parkinsonism, and Parkinson disease: A clinicopathologic study
  22. Lack of unique neuropathology in amyotrophic lateral sclerosis associated with p.K54E angiogenin (ANG) mutation
  23. ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN
  24. Neurodegeneration caused by intronic expansions of C9ORF72 is a clinically heterogeneous but pathologically distinct disease
  25. Investigating cell death mechanisms in amyotrophic lateral sclerosis using transcriptomics
  26. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
  27. Simultaneous and independent detection of C9ORF72 alleles with low and high number of GGGGCC repeats using an optimised protocol of Southern blot hybridisation
  28. Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity
  29. Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of C9ORF72
  30. Gene expression profiling in human neurodegenerative disease
  31. The C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder
  32. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study
  33. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72
  34. Insights Arising from Gene Expression Profiling in Amyotrophic Lateral Sclerosis
  35. Genetics of Familial Amyotrophic Lateral Sclerosis
  36. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology
  37. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis
  38. Brain Iron Dysregulation and the Risk of Ageing White Matter Lesions
  39. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis
  40. HFE H63D, C282Y and AGTR1 A1166C Polymorphisms and Brain White Matter Lesions in the Aging Brain
  41. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis
  42. Novel FUS/TLS Mutations and Pathology in Familial and Sporadic Amyotrophic Lateral Sclerosis
  43. Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)
  44. Broad clinical phenotypes associated with TAR-DNA binding protein (TARDBP) mutations in amyotrophic lateral sclerosis
  45. Transcriptional response of the neuromuscular system to exercise training and potential implications for ALS
  46. New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP)
  47. HSP60 IS A RARE CAUSE OF HEREDITARY SPASTIC PARAPARESIS, BUT MAY ACT AS A GENETIC MODIFIER
  48. Microarray Analysis of the Cellular Pathways Involved in the Adaptation to and Progression of Motor Neuron Injury in the SOD1 G93A Mouse Model of Familial ALS
  49. MUTATIONS IN VAPB ARE NOT ASSOCIATED WITH SPORADIC ALS
  50. Gene Expression Assays
  51. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations
  52. Clinical features of hereditary spastic paraplegia due to spastin mutation
  53. Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen
  54. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS
  55. Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis
  56. Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis
  57. No association with common Caucasian genotypes in exons 8, 13 and 14 of the human cytoplasmic dynein heavy chain gene (DNCHC1) and familial motor neuron disorders
  58. Analysis of the Cytosolic Proteome in a Cell Culture Model of Familial Amyotrophic Lateral Sclerosis Reveals Alterations to the Proteasome, Antioxidant Defenses, and Nitric Oxide Synthetic Pathways
  59. Differential gene expression in a cell culture model of SOD1-related familial motor neurone disease
  60. Mutation screening of manganese superoxide dismutase in amyotrophic lateral sclerosis
  61. Molecular and cytological investigations of phosphoglucomutase (PGM1) in the K562 cell line